MECHANISM OF DIFFERENTIATION OF FUNCTION OF CD80 & CD86
MECHANISM OF DIFFERENTIATION OF FUNCTION OF CD80 & CD86
批准号:
6349888
负责人:
Michael G Agadjanyan
金额:
$30.64万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-02-01 至 2005-01-31
关键词:
CD antigens MHC class I antigen antigen presenting cell biological signal transduction cytotoxic T lymphocyte enzyme linked immunosorbent assay gene expression genetically modified animals helper T lymphocyte immunization immunocytochemistry laboratory mouse leukocyte activation /transformation plasmids protein structure function surface antigens transfection vector vaccine virus genetics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The biological rationale for the expression of two co-stimulatory molecules (CD80 and CD86) on the membrane of professional APC is not clear. Many results demonstrate that both molecules provide equivalent co-stimulatory signals to T-cells. Different roles for CD80 and CD86 in the activation of distinct subpopulations of T-cells have also been described in both in vivo and in vitro models. Our published data along with other results indicate that CD86, but not CD80, stimulates cellular immune responses during DNA vaccination of mice. The important question is why CD86, but not CD80 is required for augmentation of T-cell response after vaccination? Based on our results we suggest several mechanisms to explain these cell responses after vaccination? Based on our results we suggest several mechanisms to explain these functional differences between CD80 and CD86 molecules. First, expression of MHC class I and CD86, but not CD80 along with immunogen may induce local invasion of immunocompetent cells crucial for generation of immune responses. Second, CD80 and CD86 may activate different subpopulations of T-cells. Third, the triggering of receptors with CD80 and CD86 molecules may supply different signals to T-cells. Finally, the ligation of CD86, but not CD80 on the surface of APC could provide important signal to these cells and in turn induce production of certain molecules such as cytokines/lymphokines/chemokines, which are important for T cell activation. To evaluate these hypotheses we propose using DNA immunization as a model system to investigate the following: 1.) The differential effects of CD80 and CD86 expression in the microenvironment of MHC class I positive or negative muscle tissues (i.e. the invasion of immunocompetent cells at the site of DNA inoculation). 2). The activation of different subsets of CTL (CD4+ or C8+) and T helper cells (Th1 or Th2) after co-immunization with immunogen and CD80/CD86 expressing plasmids. 3). The functional region/s of human CD86 molecule involved in enhancement of cellular immune responses after co-immunization with DNA encoding immunogen and different CD80/CD86 mutant molecules. 4) The synergistic effect of co- stimulatory molecules and cytokines produced by professional APC, on T-cell activation after DNA vaccination. 5). The differential expression of genes after ligation of CD86 versus CD80 on muscle cells and professional APC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Manufacturing of New Batch AV-1959D Drug Product and Placebo for Phase 1 Trial
-
批准号:10732215
-
项目类别:
-
资助金额:$69.9万
-
财政年份:2022
-
负责人:Michael G Agadjanyan
-
依托单位:
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
-
批准号:10340654
-
项目类别:
-
资助金额:$268.07万
-
财政年份:2022
-
负责人:Michael G Agadjanyan
-
依托单位:
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
-
批准号:10571883
-
项目类别:
-
资助金额:$240.86万
-
财政年份:2022
-
负责人:Michael G Agadjanyan
-
依托单位:
Manufacturing of Drug Product, Dual Aβ/tau Vaccine for Clinical Trials
-
批准号:10667237
-
项目类别:
-
资助金额:$227.0万
-
财政年份:2019
-
负责人:Michael G Agadjanyan
-
依托单位:
Evaluation of Safe and Immunogenic Dose of AD Vaccine in aged non-human primates: Prelude to Phase 1 Preventive Vaccinations
-
批准号:10433497
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2019
-
负责人:Michael G Agadjanyan
-
依托单位:
Cooperative program U01 AG060965 Supplement: "Preparation of IND for Dual Aβ/Tau AD Vaccine for submission to FDA"
-
批准号:10505652
-
项目类别:
-
资助金额:$29.77万
-
财政年份:2019
-
负责人:Michael G Agadjanyan
-
依托单位:
Repurposing of Universal and Immunogenic MultiTEP Platform Designed for AD to Develop SARS-CoV-2 Multiepitope Vaccine
-
批准号:10162389
-
项目类别:
-
资助金额:$38.91万
-
财政年份:2019
-
负责人:Michael G Agadjanyan
-
依托单位:
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial
-
批准号:10364623
-
项目类别:
-
资助金额:$223.8万
-
财政年份:2019
-
负责人:Michael G Agadjanyan
-
依托单位:
Combining AD Epitope Vaccine with Innate Immunity
-
批准号:9439835
-
项目类别:
-
资助金额:$1.02万
-
财政年份:2017
-
负责人:Michael G Agadjanyan
-
依托单位:
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND
-
批准号:8887223
-
项目类别:
-
资助金额:$115.22万
-
财政年份:2015
-
负责人:Michael G Agadjanyan
-
依托单位:
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND
-
批准号:9264954
-
项目类别:
-
资助金额:$125.38万
-
财政年份:2015
-
负责人:Michael G Agadjanyan
-
依托单位:
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
-
批准号:7761719
-
项目类别:
-
资助金额:$37.78万
-
财政年份:2008
-
负责人:Michael G Agadjanyan
-
依托单位:
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
-
批准号:7564750
-
项目类别:
-
资助金额:$38.16万
-
财政年份:2008
-
负责人:Michael G Agadjanyan
-
依托单位:
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
-
批准号:8214522
-
项目类别:
-
资助金额:$37.4万
-
财政年份:2008
-
负责人:Michael G Agadjanyan
-
依托单位:
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
-
批准号:8029499
-
项目类别:
-
资助金额:$37.4万
-
财政年份:2008
-
负责人:Michael G Agadjanyan
-
依托单位:
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
-
批准号:7911467
-
项目类别:
-
资助金额:$9.97万
-
财政年份:2008
-
负责人:Michael G Agadjanyan
-
依托单位:
Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
-
批准号:7467772
-
项目类别:
-
资助金额:$38.16万
-
财政年份:2008
-
负责人:Michael G Agadjanyan
-
依托单位:
Combining AD Epitope Vaccine with Innate Immunity
-
批准号:8973559
-
项目类别:
-
资助金额:$62.3万
-
财政年份:2004
-
负责人:Michael G Agadjanyan
-
依托单位:
Combining AD Epitope Vaccine with Innate Immunity
-
批准号:8074363
-
项目类别:
-
资助金额:$44.64万
-
财政年份:2004
-
负责人:Michael G Agadjanyan
-
依托单位:
Combining AD Epitope Vaccine with Innate Immunity
-
批准号:8465918
-
项目类别:
-
资助金额:$40.44万
-
财政年份:2004
-
负责人:Michael G Agadjanyan
-
依托单位:
海外基金